An official website of the United States government
NIH Guide: Weekly Index for March 25, 2022
Weekly NIH Funding Opportunities and Notices
March 25, 2022
Policy Notices
-
Upcoming Changes to the Federal Financial Report (FFR) Beginning April 1, 2022
(NOT-OD-22-099)National Institutes of HealthAgency for Healthcare Research and Quality
General Notices
-
Pre-Application Webinar for NOT-CA-22-056, Administrative Supplements to Support Germline Genome-wide Genotyping and Sequencing of Existing Samples from Minority Racial/Ethnic Populations and Sharing of Associated Epidemiologic Data
(NOT-CA-22-064)National Cancer InstituteNational Institute of Environmental Health Sciences
-
Notice of NCI Participation in RFA-MD-22-008, Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
(NOT-CA-22-066)National Cancer Institute
-
RESCINDED - Notice of Participation of Additional NIH Institutes and Centers in PAR-20-153: Science Education Partnership Awards (SEPA) (R25-Clinical Trial Not Allowed)
(NOT-HG-22-006)National Human Genome Research InstituteNational Institute on Alcohol Abuse and AlcoholismNational Institute on AgingNational Institute of Allergy and Infectious DiseasesNational Institute on Drug AbuseNational Institute of Dental and Craniofacial ResearchNational Institute of Diabetes and Digestive and Kidney DiseasesNational Eye InstituteEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Mental HealthNational Institute of Nursing ResearchNational Institute of Neurological Disorders and StrokeNational Center for Advancing Translational SciencesNational Center for Complementary and Integrative HealthNational Institute of Biomedical Imaging and BioengineeringOffice of Research on Women's HealthNational Institute on Minority Health and Health DisparitiesNational Center for Advancing Translational Sciences
-
Request for Information (RFI): Inviting Input on NIDAs Racial Equity Initiative Action Plan
(NOT-DA-22-052)National Institute on Drug Abuse
Notice of Changes to Funding Opportunities
-
Notice of Change to Update Other Clinical Trial-related Attachments in PAR-21-241 NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
(NOT-AT-22-017)National Center for Complementary and Integrative Health
-
Notice of Termination of RFA-DA-22-033, "Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)"
(NOT-DA-22-059)National Institute on Drug Abuse
-
Notice of Change to Assistance Listing Number(s) for PA-21-151 "NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)"
(NOT-ES-22-008)National Institute of Environmental Health Sciences
-
Notice of NICHD Participation in PAR-22-000 "Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)"
(NOT-HD-22-012)Eunice Kennedy Shriver National Institute of Child Health and Human Development
-
Notice of Application Submission and Due Date Changes for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)"
(NOT-HL-22-015)National Heart, Lung, and Blood Institute
-
Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)"
(NOT-HL-22-016)National Heart, Lung, and Blood Institute
-
Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"
(NOT-HL-22-017)National Heart, Lung, and Blood Institute
-
Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"
(NOT-HL-22-018)National Heart, Lung, and Blood Institute
-
Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)"
(NOT-HL-22-019)National Heart, Lung, and Blood Institute
-
Notice to Rescind NOT-NS-22-053 "Notice of Special Interest (NOSI): Pain-Focused Administrative Supplements for NINDS Grants that are Not Focused on Pain Research"
(NOT-NS-22-092)National Institute of Neurological Disorders and Stroke
-
Notice of Change in Eligibility to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
(NOT-TR-22-024)National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
-
Notice of Change in Award Information to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
(NOT-TR-22-025)National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
-
Notice of Change in Funding Opportunity Description and Application and Submission Information to PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional)
(NOT-TR-22-026)National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
Notices of Intent to Publish
-
Notice of Intent to Publish a Funding Opportunity Announcement for Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed)
(NOT-DK-22-018)National Institute of Diabetes and Digestive and Kidney Diseases
-
Notice of Intent to Publish a Funding Opportunity Announcement for Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed)
(NOT-HD-22-006)Eunice Kennedy Shriver National Institute of Child Health and Human Development
-
Notice of Intent to Publish a Funding Opportunity Announcement for Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early Stage Development (UG3/UH3 Clinical Trial Not Allowed)
(NOT-NS-22-086)National Institute of Neurological Disorders and StrokeNational Institute on Drug AbuseNational Institute of Environmental Health SciencesNational Eye Institute
-
Notice of Intent to Publish a Funding Opportunity Announcement for Impact of the Microbiome Gut-Brain Axis on ADRD (R01 Clinical Trial Not Allowed)
(NOT-NS-22-088)National Institute of Neurological Disorders and Stroke
Notices of Special Interest
-
Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Stimulate or Strengthen Global Cancer Health Disparities Research
(NOT-CA-22-057)National Cancer Institute
-
Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging
(NOT-EB-22-006)National Institute of Biomedical Imaging and Bioengineering
-
Notice of Special Interest (NOSI): Research using implementation science to support the delivery of evidence-based practices in community-based mental or general medical healthcare settings
(NOT-MH-22-170)National Institute of Mental HealthNational Institute on Drug Abuse
-
Notice of Special Interest(NOSI): Recruitment Innovation Center (RIC) Topic Area for Limited Competition: Clinical and Translational Science Award Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Optional)
(NOT-TR-22-020)National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
-
Notice of Special Interest (NOSI) Trial Innovation Center (TIC) Topic Area for Limited Competition: Clinical and Translational Science Award (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Optional)
(NOT-TR-22-021)National Center for Advancing Translational SciencesNational Center for Advancing Translational Sciences
Funding Opportunities
-
Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
(PAR-22-076)National Institute of Neurological Disorders and StrokeApplication Receipt Date(s): Multiple dates, see announcement.
-
Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
(PAR-22-126)National Institute of General Medical SciencesNational Institute on AgingNational Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
(PAR-22-127)National Institute of General Medical SciencesNational Institute on AgingNational Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54 Clinical Trial Not Allowed)
(RFA-CA-22-012)National Cancer InstituteApplication Receipt Date(s): November 01, 2022
-
PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed)
(RFA-CA-22-013)National Cancer InstituteApplication Receipt Date(s): November 01, 2022
-
Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
(RFA-CA-22-017)National Cancer InstituteNational Institute on Drug AbuseNational Institute of Biomedical Imaging and BioengineeringApplication Receipt Date(s): Not Applicable
-
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
(RFA-CA-22-021)National Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
(RFA-CA-22-022)National Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
(RFA-CA-22-023)National Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
(RFA-CA-22-024)National Cancer InstituteApplication Receipt Date(s): Multiple dates, see announcement.
-
Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
(RFA-DA-23-014)National Institute on Drug AbuseApplication Receipt Date(s): August 11, 2022
-
Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
(RFA-MD-22-008)National Institute on Minority Health and Health DisparitiesNational Cancer InstituteApplication Receipt Date(s): November 13, 2022
-
Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed)
(RFA-MH-22-140)National Institute of Mental HealthOffice of Behavioral and Social Sciences ResearchNational Institute on Minority Health and Health DisparitiesApplication Receipt Date(s): June 20, 2023
-
Understanding Suicide Risk and Protective Factors among Black Youth (R21 Clinical Trial Not Allowed)
(RFA-MH-22-141)National Institute of Mental HealthApplication Receipt Date(s): June 20, 2023
-
BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
(RFA-MH-22-220)National Institute of Mental HealthNational Institute on Alcohol Abuse and AlcoholismNational Institute on AgingNational Institute on Drug AbuseNational Institute on Deafness and Other Communication DisordersNational Eye InstituteEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Neurological Disorders and StrokeNational Center for Complementary and Integrative HealthNational Institute of Biomedical Imaging and BioengineeringApplication Receipt Date(s): April 12, 2023
NIH Funding Opportunities are also available in an RSS feed (Really Simple Syndication).
Subscribe/Unsubscribe from the NIH Guide Weekly TOC LISTSERV.
This page last updated on: January 13, 2025
For technical issues E-mail OER Webmaster